Amplyx Pharmaceuticals is Acquired by Pfizer Inc

Pfizer Inc. announced that it has acquired Amplyx Pharmaceuticals, Inc which was a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix , is a novel investigational asset under development for the treatment of invasive fungal infections.

More than 1.5 million cases of invasive fungal infections occur worldwide each year, with mortality rates as high as 30-80% across infection types. Fosmanogepix has a novel mechanism of action with the potential to target fungal strains resistant to standard of care therapy. There are only three classes of antifungal medications currently available, antifungal resistance can severely limit treatment options; a potential new therapeutic class may therefore be of importance for both physicians and patients.There has been no novel therapeutic class of antifungal therapies approved by the U.S. Food and Drug Administration in nearly 20 years.

Angela Lukin, Global President, Pfizer Inc said that that the pandemic has been a stark reminder of the impact of infectious diseases, highlighting the continuous need for new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral and fungal infections. They are committed to helping patients suffering from infectious diseases, continuously seeking opportunities to build our portfolio of anti-infective therapies. They have invested in assets that, if approved, could help address drug-resistant bacterial infections and critical viral infections; with this acquisition, they look forward to progressing the development of a novel antifungal

Fosmanogepix is currently in Phase 2 clinical trials evaluating the safety and efficacy of both intravenous and oral formulations for the treatment of patients with life-threatening invasive fungal infections caused by molds, yeasts and rare molds. Fosmanogepix has indicated broad-spectrum activity in-vitro and has shown wide distribution to various tissues including the brain, lung, kidney and eye. With both IV and oral formulations in development, Fosmanogepix may enable the transition from IV to oral, which leads to enabling the benefit of patients, the continuation of treatment outside the hospital.